DOBI MEDICAL SYSTEMS EXPANDS SENIOR MANAGEMENT TEAM
Mahwah, NJ, April 18, 2001.
DOBI Medical Systems, LLC, the high-tech medical device company that has
developed a unique means of differentiating malignant from benign tumors
in the breast by identifying angiogenesis, announced today that it has
expanded its senior management team this year with the addition of three
new Vice Presidents.
Dale A. Johnson has been named Group Vice President for Business Development. Mr. Johnson brings over 19 years of experience in the medical and biotechnology industry and during the last five years he served as the president of a medical communications company. Prior to that he was a senior executive in marketing at Glaxo, Inc. where he served as the international marketing manager for both pharmaceutical and medical products.
Julie G. Martin has been named Vice President, Marketing. Ms. Martin has extensive senior executive clinical, marketing, and business development experience÷with the last 8 years in womenâs health. Ms. Martin is currently on the Board of Directors of the San Diego Affiliate of the Susan G. Komen Breast Cancer Foundation, where she helps others from her own experiences as a breast cancer survivor. She also speaks nationally on a variety of women's health issues.
In announcing the new members of the management team, Phillip C. Thomas, President and Chief Executive Officer of DOBI Medical Systems said, äWe are very enthusiastic about the addition of these three key executives. Each is an outstanding professional with important and valuable background, experience and credentials to help DOBI Medical Systems continue to grow. We expect them to make significant contributions in each of their areas of expertise that will enable us to move forward immediately with a number of valuable initiatives.
About DOBI Medical Systems
Except for historical information contained herein, the matters discussed in this news release may contain forward-looking statements that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not guarantees of future performance due to factors that could cause actual results to differ materially including, but not limited to, results of future clinical trials, technical risks associated with new technology development, government regulatory approval, market acceptance of our product, competition and technological change.
For further information:
DOBI Medical International